CA3064345C - Compositions comprenant des enveloppes de vih modifiees - Google Patents

Compositions comprenant des enveloppes de vih modifiees

Info

Publication number
CA3064345C
CA3064345C CA3064345A CA3064345A CA3064345C CA 3064345 C CA3064345 C CA 3064345C CA 3064345 A CA3064345 A CA 3064345A CA 3064345 A CA3064345 A CA 3064345A CA 3064345 C CA3064345 C CA 3064345C
Authority
CA
Canada
Prior art keywords
envelope
hiv
sosip
seq
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3064345A
Other languages
English (en)
Other versions
CA3064345A1 (fr
Inventor
Barton F. Haynes
David Montefiori
Kevin J. WIEHE
Kevin O. SAUNDERS
Celia C. LaBranche
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Priority claimed from PCT/US2018/034772 external-priority patent/WO2018218225A1/fr
Publication of CA3064345A1 publication Critical patent/CA3064345A1/fr
Application granted granted Critical
Publication of CA3064345C publication Critical patent/CA3064345C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des immunogènes et des procédés pour induire des réponses immunitaires, notamment des procédés de stimulation et de maturation de cellules B de lignée germinale par ingénierie inverse d'enveloppes de VIH-1.
CA3064345A 2017-05-25 2018-05-25 Compositions comprenant des enveloppes de vih modifiees Active CA3064345C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511226P 2017-05-25 2017-05-25
US62/511,226 2017-05-25
US201762565952P 2017-09-29 2017-09-29
US62/565,952 2017-09-29
PCT/US2018/034772 WO2018218225A1 (fr) 2017-05-25 2018-05-25 Compositions comprenant des enveloppes de vih modifiées

Publications (2)

Publication Number Publication Date
CA3064345A1 CA3064345A1 (fr) 2018-11-29
CA3064345C true CA3064345C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
Zhang et al. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
US11884704B2 (en) Compositions comprising HIV envelopes to induce CH235 lineage antibodies
US11814413B2 (en) Compositions comprising modified HIV envelopes
Overbaugh et al. The antibody response against HIV-1
US6815201B2 (en) HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
EP2765138B1 (fr) Glycoprotéine d'enveloppe du VIH-1
US20100041875A1 (en) Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric coplexes, and uses thereof
US11246920B2 (en) Compositions and methods for inducing HIV-1 antibodies
CA3055204A1 (fr) Compositions et procedes pour induire des anticorps anti-vih-1
US11318197B2 (en) Compositions and methods for inducing HIV-1 antibodies
WO2012003234A2 (fr) Immunogènes trimères d'env
WO2019070730A1 (fr) Enveloppes mosaïques du vih-1 pour induire des réponses d'adcc
WO2016014721A2 (fr) Compositions comprenant des enveloppes sensibles au virus ch505
CA3064345C (fr) Compositions comprenant des enveloppes de vih modifiees
WO2004053100A2 (fr) Polypeptides gp120 du virus de l'immunodeficience humaine mutants immunogenes, et leurs procedes d'utilisation
Mayr et al. Antibodies targeting the envelope of HIV‐1
Cheng Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER)
Omorodion Broadly Neutralizing Antibodies to HIV: Evolution of Structure in Three Infected Donors
Mader Anti-idiotypic antibody Ab2/3H6
Hogan Improving Vaccine Design for Viral Diseases Using Modified Antigens and Vectors
Chukwuma Immune Mechanisms Modulating the Development of Breadth in the Antibody Repertoire of HIV Infected Subjects
Agrawal Focusing immune response on key neutralizing epitopes of HIV-1 through immune complex vaccination
Ho Engineering an immunotargeting vaccine for type 1 human immunodeficiency virus
WO2016172070A1 (fr) Immunisation en essaim au moyen d'enveloppes de ch505
Benen Novel Immunogens based on the gp41 protein of Human Immunodeficiency Virus type 1 and Display Systems for their Affinity Maturation